Mr. Rashid Bux reports

BIOMARK ANNOUNCES FINANCIAL CONTRIBUTION FROM THE CITY OF QUEBEC TO SUPPORT COMMERCIALIZATION INITIATIVES OF ITS PROPRIETARY LUNG CANCER DETECTION TEST

Biomark Diagnostics Inc.'s wholly owned laboratory subsidiary, Biomark Diagnostic Solutions Inc. (BDS), has been awarded non-dilutive financing of $231,000 from the City of Quebec through its Vision Entrepreneuriale Quebec 2026 to accelerate commercialization and market development activities of its proprietary assay for early detection of lung cancer.

"Today's announcement is a significant example of the positive impact of early lung cancer detection, particularly during the 2023 lung cancer awareness month. We are privileged that the City of Quebec and its team have kept a keen eye on our infrastructure buildout and the accelerated pace of commercialization of our diagnostic assays starting with early lung cancer molecular assay which we plan to commercialize within the next six to nine months. Quebec City has been instrumental for Biomark not only for the talent pool, financial incentives but the vibrant clinical research ecosystem provided by the great partnership with the Quebec Heart and Lung Institute (IUCPQ)," said Rashid Bux chief executive officer and president of Biomark.

Biomark intends to use this financing to support business development and commercialization of its liquid biopsy assay that measures Biomarker for early detection of lung cancer. The project leverages its Quebec-based fully equipped laboratory which provides a clinical environment to develop an effective, and affordable portfolio of assays for early cancer detection and treatment management.

Mr. Bux further adds: "When we first visited Quebec in 2020, we were impressed by the calibre of IUCPQ, the clinicians, researchers and overall infrastructure support and initiatives offered by the City of Quebec. As a group, we are delighted and extremely grateful to have this financial support as we are establishing our Centre of Excellence for our lung cancer assets in Quebec City. Our soon-to-be certified lab led by Dr. Haince, and his group will offer our early lung detection tests initially in Quebec and later across Canada and North America."

2023 Lung Cancer Awareness Month

Every year in November, people come together to recognize and raise awareness of the challenges that come from a diagnosis of lung cancer. It is through this recognition that individuals and groups have helped to make a difference for lung cancer patients, caregivers, family and friends. Special events and fundraisers are just some of the ways that communities are coming together to help support patients and raise awareness.

About Biomark Diagnostics Inc.

Biomark is a leading liquid biopsy company developing a molecular diagnostics technology platform that leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the presymptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. While the company's current focus is on the commercialization of its liquid biopsy test for early detection of lung, it has a plan to expand into other hard-to-detect and treat cancers such as brain, ovarian and pancreatic.

We seek Safe Harbor.